<DOC>
	<DOC>NCT00332007</DOC>
	<brief_summary>Overall trial objectives: 1. Can treatment with tonabersat reduce the number of days with aura and/or migraine headache in patients with migraine with aura 2. How well tolerated is treatment with tonabersat The study is based on the hypothesis that the unique mechanism of action of tonabersat will inhibit some of the early events in the generation of aura and migraine headache and so be effective as prophylactic treatment</brief_summary>
	<brief_title>Tonabersat in the Prophylaxis of Migraine With Aura</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine with Aura</mesh_term>
	<criteria>Patients with an established history of migraine of at least one year meeting the diagnostic criteria of the International Classification of Headache Disorders Edition 2 (Appendix 2) and who experience at least one aura a month. Male or female patients between 1865 years of age Women of child bearing potential must be using a reliable form of contraception (defined in the protocol) for at least 3 months prior to enrolment and they must have a negative pregnancy test at screening with no intention of becoming pregnant during the study period Patients experiencing headache other than migraine or tension headache Overuse of acute migraine treatments defined as more than 14 daily doses per month with analgesics or more than 9 daily doses per month of ergots or triptans within the last two months Migraine prophylactic treatment within two months prior to entry to the trial Patients taking any of the following medications for migraine: betablockers, tricyclic antidepressants (during the last 2 months), antiepileptic dugs (during the last 2 months), calcium channel blockers, monoamine oxidase inhibitors, daily NSAIDs, daily paracetamol, high dose magnesium supplements (600mg/day). Parenteral administration of botulinum toxin is also excluded. These drugs are permitted when given for diseases other than migraine provided that, in the opinion of the investigator the dose can be kept constant throughout the trial. Patients who, in the opinion of the investigator, have significant cerebrovascular disease e.g. transient ischaemic attacks, stroke Patients who, in the opinion of the investigator, have clinically significant cardiovascular disease Patients suffering from a current clinical diagnosis of a major depressive disorder or schizophrenia Patients with renal dysfunction , defined as a serum creatinine of greater than 125% of the upper limit of normal for their age group Patients with hepatic dysfunction defined as a liver function test (AST, ALT, alkaline phosphatase, bilirubin) of greater than twice the upper limit of normal for their age group Patients with known alcohol or other substance abuse Use of an investigational drug (for any indication) within 30 days or 5 halflives, whichever is the longer, prior to screening Women who are pregnant or breast feeding Women of childbearing potential not using a reliable form of contraception Patients with any other clinically significant condition which, in the investigators opinion, would render them unsuitable for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>